Name: CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock
Brand: CORBUS PHARMACEUTICALS HOLDI
Rating: 6.5 (3 reviews)

CRBP Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

15 days ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

a month ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

a month ago - By: Corbus Pharmaceuticals Holdings, Inc.

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

3 months ago - By: Zacks Investment Research - Mentions: CGC TLRY HRMY

Can Cannabis Stocks Reverse Their Prolonged Downtrend?

3 months ago - By: The Motley Fool

Corbus (CRBP) Q2 Loss Beats Estimates

3 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

3 months ago - By: Benzinga - Mentions: CBDY CVSI GNLN CNBX ...

Cannabis Stock Gainers And Losers From July 16, 2025

4 months ago - By: Benzinga - Mentions: IIPR LBUY MRMD SNDL ...

Cannabis Stock Movers For July 15, 2025

4 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

4 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

4 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

5 months ago - By: Zacks Investment Research - Mentions: NVO LLY SKYE

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

5 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

5 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

6 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

6 months ago - By: Zacks Investment Research - Mentions: TLRY PM JAZZ

Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?

6 months ago - By: Corbus Pharmaceuticals Holdings, Inc.

CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock News

CRBP Latest News, Press Relases and Analysis

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Can Cannabis Stocks Reverse Their Prolonged Downtrend?

Corbus (CRBP) Q2 Loss Beats Estimates

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Cannabis Stock Gainers And Losers From July 16, 2025

Cannabis Stock Movers For July 15, 2025

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update